Nganou-Makamdop Krystelle
Department of Internal Medicine 3, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf023.
Potent inflammatory responses stemming from innate and T cell activation are initiated during acute human immunodeficiency virus infection. Suppression of the virus replication by antiretroviral therapy reduces but does not normalize immune activation. By now, it is clear that residual immune activation can persist even after years of antiretroviral therapy and associates with increased risks for co-morbidities, thereby raising interest for strategies that can resolve the residual immune activation in people with human immunodeficiency virus on antiretrovirals. This brief review reports the human studies with various drugs with anti-inflammatory properties and their effects on measures of systemic immune activation on people with human immunodeficiency virus. Along with the possible reasons for conflicting outcomes, considerations for ongoing and future approaches are outlined.
在急性人类免疫缺陷病毒感染期间，由先天免疫和T细胞激活引发的强烈炎症反应就会启动。抗逆转录病毒疗法对病毒复制的抑制作用可降低免疫激活水平，但无法使其恢复正常。目前已经明确，即使经过数年的抗逆转录病毒治疗，残余的免疫激活仍可能持续存在，并与共病风险增加相关，因此，人们对能够解决接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者残余免疫激活问题的策略越来越感兴趣。这篇简短的综述报告了针对具有抗炎特性的各种药物的人体研究，以及它们对人类免疫缺陷病毒感染者全身免疫激活指标的影响。同时还概述了结果相互矛盾的可能原因以及对当前和未来研究方法的考虑。
